Publications by authors named "O Galvao Filho"
Background: The use of blood biomarkers predictive of the presence of amyloid Aβ and ApoE4 is an effective tool to facilitate a timely AD diagnosis. About a third of dementia cases can be attributed to potentially modifiable risk factors, and the incidence of the disease can be reduced by addressing these factors. Memory Workshops integrated with early detection and actions on risk factors is an operational strategy that is both therapeutic and preventive.
View Article and Find Full Text PDFBackground: In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory multiple myeloma. We report here patient-reported outcomes.
Methods: In the ongoing, phase 3, open-label CARTITUDE-4 study, patients were recruited from 81 sites in the USA, Europe, Asia, and Australia, and were randomly assigned 1:1 to cilta-cel (target, 0·75 × 10 CAR-T cells/kg) or standard of care (daratumumab, pomalidomide, and dexamethasone; pomalidomide, bortezomib, and dexamethasone).
Objective: This study aims to determine the prevalence of oropharyngeal dysphagia (OD) in children, as diagnosed through instrumental evaluation, and to identify associated risk factors.
Methods: A systematic search was conducted across six databases (Embase, LILACS, LIVIVO, PubMed/MEDLINE, Scopus, and Web of Science), as well as gray literature sources (ASHA, Google Scholar, and ProQuest). Studies involving children (under 12 years of age), diagnosed using instrumental methods such as videofluoroscopic swallow study (VFSS) or fiberoptic endoscopic evaluation of swallowing (FEES), were included.
Friedreich's Ataxia (FRDA) is the most common autosomal recessive ataxia worldwide and is caused by biallelic unstable intronic GAA expansions at FXN. With its limited therapy and the recent approval of the first disease-modifying agent for FRDA, the search for biological markers is urgently needed to assist and ease the development of therapies. MiRNAs have emerged as promising biomarkers in various medical fields such as oncology, cardiology, epilepsy and neurology as well.
View Article and Find Full Text PDFArticle Synopsis
- Identifying biomarkers for COVID-19 outcomes is essential for better managing high-risk patients and improving survival chances, particularly through early antiviral medication administration.
- A study involving 297 COVID-19 patients in Belo Horizonte, Brazil, explored the relationship between hematological parameters and disease severity using statistical analysis and machine learning.
- Findings indicate that monocyte percentage and granulocyte-to-lymphocyte ratio can effectively predict hospitalization risk, making these simple blood test parameters valuable tools for managing treatment in various healthcare settings.